1:"$Sreact.fragment"
a:I[5014,["/_next/static/chunks/236aw131lsvrc.js","/_next/static/chunks/1-8s9_t85wwr4.js","/_next/static/chunks/3p66hazs5-2j3.js","/_next/static/chunks/40jyur0wxtonc.js"],"default"]
b:I[92604,["/_next/static/chunks/236aw131lsvrc.js","/_next/static/chunks/1-8s9_t85wwr4.js","/_next/static/chunks/3p66hazs5-2j3.js","/_next/static/chunks/40jyur0wxtonc.js"],"SpikeTherapeuticsTable"]
c:I[97367,["/_next/static/chunks/236aw131lsvrc.js","/_next/static/chunks/1-8s9_t85wwr4.js","/_next/static/chunks/3p66hazs5-2j3.js"],"OutletBoundary"]
d:"$Sreact.suspense"
2:T61ae,{"@context":"https://schema.org","@type":["MedicalWebPage","Dataset"],"name":"Spike Protein Therapeutics","description":"COVID-19 and Long COVID therapeutics claimed to block, degrade, or clear SARS-CoV-2 spike protein: mAbs, apheresis, nattokinase, autophagy inducers, with clinical support tiers.","dateModified":"2026-07-06","about":{"@type":"MedicalCondition","name":"SARS-CoV-2 Spike Protein Persistence"},"mainEntity":{"@type":"ItemList","numberOfItems":26,"itemListElement":[{"@type":"ListItem","position":1,"item":{"@type":"MedicalTherapy","name":"Pemivibart (INV-202)","description":"Neutralizes spike; prevents ACE2 binding","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Monoclonal antibody"},{"@type":"PropertyValue","name":"Target","value":"block"},{"@type":"PropertyValue","name":"Clinical support","value":"FDA-authorized"},{"@type":"PropertyValue","name":"Evidence level","value":"Medium"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"No"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":2,"item":{"@type":"MedicalTherapy","name":"Sotrovimab","description":"Spike neutralization (conserved epitope)","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Monoclonal antibody"},{"@type":"PropertyValue","name":"Target","value":"block"},{"@type":"PropertyValue","name":"Clinical support","value":"FDA-authorized"},{"@type":"PropertyValue","name":"Evidence level","value":"Medium"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"No"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":3,"item":{"@type":"MedicalTherapy","name":"Evusheld (tixagevimab/cilgavimab)","description":"Dual spike neutralization","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Monoclonal antibody combo"},{"@type":"PropertyValue","name":"Target","value":"block"},{"@type":"PropertyValue","name":"Clinical support","value":"FDA-authorized"},{"@type":"PropertyValue","name":"Evidence level","value":"Medium"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"No"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":4,"item":{"@type":"MedicalTherapy","name":"Therapeutic apheresis / plasmapheresis","description":"Physical removal of circulating spike, autoantibodies, lipids","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Blood purification"},{"@type":"PropertyValue","name":"Target","value":"clear"},{"@type":"PropertyValue","name":"Clinical support","value":"Case series / pilot"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"Clinical improvement of long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis","author":"Achleitner M, et al.","isPartOf":{"@type":"Periodical","name":"Molecular Psychiatry"},"datePublished":"2023","sameAs":"https://doi.org/10.1038/s41380-023-02084-1","url":"https://pubmed.ncbi.nlm.nih.gov/37291234/"},{"@type":"ScholarlyArticle","name":"SPEAR Trial — spike protein apheresis research","author":"ClinicalTrials.gov","isPartOf":{"@type":"Periodical","name":"Clinical trial registry"},"datePublished":"2024","url":"https://clinicaltrials.gov/"}]}},{"@type":"ListItem","position":5,"item":{"@type":"MedicalTherapy","name":"SPEAR Trial (spike-directed apheresis)","description":"Protocolized spike reduction via apheresis","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Clinical trial"},{"@type":"PropertyValue","name":"Target","value":"clear"},{"@type":"PropertyValue","name":"Clinical support","value":"Ongoing trial"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"SPEAR Trial — spike protein apheresis research","author":"ClinicalTrials.gov","isPartOf":{"@type":"Periodical","name":"Clinical trial registry"},"datePublished":"2024","url":"https://clinicaltrials.gov/"}]}},{"@type":"ListItem","position":6,"item":{"@type":"MedicalTherapy","name":"Nattokinase","description":"In vitro degradation of recombinant spike at 2.5–25 µg/mL","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Protease supplement"},{"@type":"PropertyValue","name":"Target","value":"degrade"},{"@type":"PropertyValue","name":"Clinical support","value":"In vitro / in silico only"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2","author":"Tanikawa T, et al.","isPartOf":{"@type":"Periodical","name":"Molecules"},"datePublished":"2022","sameAs":"https://doi.org/10.3390/molecules27238405","url":"https://www.mdpi.com/1420-3049/27/23/8405"},{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":7,"item":{"@type":"MedicalTherapy","name":"Bromelain","description":"Proposed spike degradation / anti-inflammatory proteolysis","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Protease supplement"},{"@type":"PropertyValue","name":"Target","value":"degrade"},{"@type":"PropertyValue","name":"Clinical support","value":"In vitro / in silico only"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":8,"item":{"@type":"MedicalTherapy","name":"Lumbrokinase / serrapeptase","description":"Fibrin degradation; proposed microclot clearance","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Fibrinolytic enzymes"},{"@type":"PropertyValue","name":"Target","value":"indirect"},{"@type":"PropertyValue","name":"Clinical support","value":"Theoretical / review only"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology","author":"Halma MTJ, Marik PE, Saleeby YM","isPartOf":{"@type":"Periodical","name":"Endocrine and Metabolic Science"},"datePublished":"2024","sameAs":"https://doi.org/10.1016/j.endmts.2024.100163","url":"https://doi.org/10.1016/j.endmts.2024.100163"}]}},{"@type":"ListItem","position":9,"item":{"@type":"MedicalTherapy","name":"Ivermectin","description":"Proposed disruption of spike–ACE2 interface (in silico/docking)","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Antiparasitic"},{"@type":"PropertyValue","name":"Target","value":"block"},{"@type":"PropertyValue","name":"Clinical support","value":"RCT negative/mixed"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"No"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":10,"item":{"@type":"MedicalTherapy","name":"Quercetin","description":"Proposed ACE2/spike interface disruption; TMPRSS2 docking (in silico)","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Flavonoid"},{"@type":"PropertyValue","name":"Target","value":"block"},{"@type":"PropertyValue","name":"Clinical support","value":"RCT negative/mixed"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":11,"item":{"@type":"MedicalTherapy","name":"Nicotine / α7nAChR agonism","description":"α7nAChR agonism; proposed ACE2 downregulation; anti-inflammatory","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Cholinergic modulator"},{"@type":"PropertyValue","name":"Target","value":"both"},{"@type":"PropertyValue","name":"Clinical support","value":"Theoretical / review only"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":12,"item":{"@type":"MedicalTherapy","name":"N-Acetylcysteine (NAC)","description":"Proposed ACE2 interface disruption; TLR modulation; glutathione precursor","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Antioxidant / mucolytic"},{"@type":"PropertyValue","name":"Target","value":"both"},{"@type":"PropertyValue","name":"Clinical support","value":"Case series / pilot"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":13,"item":{"@type":"MedicalTherapy","name":"Curcumin","description":"TLR1 modulation (Halma interface inhibitor table)","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Polyphenol"},{"@type":"PropertyValue","name":"Target","value":"indirect"},{"@type":"PropertyValue","name":"Clinical support","value":"In vitro / in silico only"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":14,"item":{"@type":"MedicalTherapy","name":"Colchicine","description":"Anti-inflammatory; indirect reduction of spike-mediated inflammation","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Anti-inflammatory"},{"@type":"PropertyValue","name":"Target","value":"indirect"},{"@type":"PropertyValue","name":"Clinical support","value":"RCT negative/mixed"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"No"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":15,"item":{"@type":"MedicalTherapy","name":"Metformin","description":"Upregulates autophagy; proposed spike aggregate clearance","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Autophagy inducer (off-label proposals)"},{"@type":"PropertyValue","name":"Target","value":"clear"},{"@type":"PropertyValue","name":"Clinical support","value":"Ongoing trial"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology","author":"Halma MTJ, Marik PE, Saleeby YM","isPartOf":{"@type":"Periodical","name":"Endocrine and Metabolic Science"},"datePublished":"2024","sameAs":"https://doi.org/10.1016/j.endmts.2024.100163","url":"https://doi.org/10.1016/j.endmts.2024.100163"},{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":16,"item":{"@type":"MedicalTherapy","name":"Rapamycin (sirolimus)","description":"Autophagy enhancement; proposed clearance of spike aggregates","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"mTOR inhibitor / autophagy inducer"},{"@type":"PropertyValue","name":"Target","value":"clear"},{"@type":"PropertyValue","name":"Clinical support","value":"Theoretical / review only"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology","author":"Halma MTJ, Marik PE, Saleeby YM","isPartOf":{"@type":"Periodical","name":"Endocrine and Metabolic Science"},"datePublished":"2024","sameAs":"https://doi.org/10.1016/j.endmts.2024.100163","url":"https://doi.org/10.1016/j.endmts.2024.100163"}]}},{"@type":"ListItem","position":17,"item":{"@type":"MedicalTherapy","name":"Spermidine / resveratrol","description":"Autophagy upregulation per Halma autophagy review","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Autophagy-promoting nutraceuticals"},{"@type":"PropertyValue","name":"Target","value":"clear"},{"@type":"PropertyValue","name":"Clinical support","value":"In vitro / in silico only"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology","author":"Halma MTJ, Marik PE, Saleeby YM","isPartOf":{"@type":"Periodical","name":"Endocrine and Metabolic Science"},"datePublished":"2024","sameAs":"https://doi.org/10.1016/j.endmts.2024.100163","url":"https://doi.org/10.1016/j.endmts.2024.100163"}]}},{"@type":"ListItem","position":18,"item":{"@type":"MedicalTherapy","name":"Intermittent fasting / caloric restriction","description":"Fasting-induced autophagy; proposed spike clearance","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Lifestyle intervention"},{"@type":"PropertyValue","name":"Target","value":"clear"},{"@type":"PropertyValue","name":"Clinical support","value":"Theoretical / review only"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology","author":"Halma MTJ, Marik PE, Saleeby YM","isPartOf":{"@type":"Periodical","name":"Endocrine and Metabolic Science"},"datePublished":"2024","sameAs":"https://doi.org/10.1016/j.endmts.2024.100163","url":"https://doi.org/10.1016/j.endmts.2024.100163"}]}},{"@type":"ListItem","position":19,"item":{"@type":"MedicalTherapy","name":"Azithromycin","description":"CD147 downregulation (Halma interface inhibitor table)","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Antibiotic"},{"@type":"PropertyValue","name":"Target","value":"block"},{"@type":"PropertyValue","name":"Clinical support","value":"RCT negative/mixed"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"No"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":20,"item":{"@type":"MedicalTherapy","name":"Anti-CD147 antibody (meplazumab)","description":"Blocks CD147–spike interaction","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Monoclonal antibody"},{"@type":"PropertyValue","name":"Target","value":"block"},{"@type":"PropertyValue","name":"Clinical support","value":"Case series / pilot"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"No"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":21,"item":{"@type":"MedicalTherapy","name":"Nirmatrelvir/ritonavir (Paxlovid)","description":"Inhibits viral replication; may reduce spike production during active infection","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Antiviral"},{"@type":"PropertyValue","name":"Target","value":"indirect"},{"@type":"PropertyValue","name":"Clinical support","value":"FDA-approved (COVID-19)"},{"@type":"PropertyValue","name":"Evidence level","value":"Medium"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":22,"item":{"@type":"MedicalTherapy","name":"Remdesivir","description":"Reduces viral replication → less neoantigen production","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Antiviral"},{"@type":"PropertyValue","name":"Target","value":"indirect"},{"@type":"PropertyValue","name":"Clinical support","value":"FDA-approved (COVID-19)"},{"@type":"PropertyValue","name":"Evidence level","value":"Medium"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"No"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":23,"item":{"@type":"MedicalTherapy","name":"NIH RECOVER","description":"Multi-intervention long COVID trials","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Research program"},{"@type":"PropertyValue","name":"Target","value":"indirect"},{"@type":"PropertyValue","name":"Clinical support","value":"Ongoing trial"},{"@type":"PropertyValue","name":"Evidence level","value":"Medium"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"RECOVER — Researching COVID to Enhance Recovery","author":"NIH RECOVER Initiative","isPartOf":{"@type":"Periodical","name":"NIH program"},"datePublished":"2024","url":"https://recovercovid.org/"}]}},{"@type":"ListItem","position":24,"item":{"@type":"MedicalTherapy","name":"NRICM101 (traditional formula)","description":"Neurovascular protection in spike-administered hACE2 mice","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Herbal compound"},{"@type":"PropertyValue","name":"Target","value":"indirect"},{"@type":"PropertyValue","name":"Clinical support","value":"Case series / pilot"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"The dose makes the poison: Translating in vivo and in vitro spike protein concentrations to clinical effects","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Manuscript / review (in preparation)"},"datePublished":"2026","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":25,"item":{"@type":"MedicalTherapy","name":"Hyperbaric oxygen (HBOT)","description":"Tissue oxygenation; proposed neurovascular recovery","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Adjunct therapy"},{"@type":"PropertyValue","name":"Target","value":"indirect"},{"@type":"PropertyValue","name":"Clinical support","value":"Case series / pilot"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}},{"@type":"ListItem","position":26,"item":{"@type":"MedicalTherapy","name":"Low-dose naltrexone (LDN)","description":"Immune modulation in long COVID (not spike-specific)","additionalProperty":[{"@type":"PropertyValue","name":"Category","value":"Immunomodulator"},{"@type":"PropertyValue","name":"Target","value":"indirect"},{"@type":"PropertyValue","name":"Clinical support","value":"Case series / pilot"},{"@type":"PropertyValue","name":"Evidence level","value":"Low"},{"@type":"PropertyValue","name":"Long COVID/PASC relevance","value":"Yes"}],"citation":[{"@type":"ScholarlyArticle","name":"The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury","author":"Halma MTJ, et al.","isPartOf":{"@type":"Periodical","name":"Advances in Virology"},"datePublished":"2025","sameAs":"https://doi.org/10.1155/av/7990876","url":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876"}]}}]}}0:{"rsc":["$","$1","c",{"children":[["$","div",null,{"children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],"$L3","$L4","$L5","$L6","$L7"]}],["$L8"],"$L9"]}],"isPartial":false,"staleTime":300,"varyParams":null,"buildId":"ouB_kPb3CWuV1XWSdyqtI"}
3:["$","header",null,{"className":"mb-8","children":[["$","h1",null,{"className":"text-3xl font-bold tracking-tight text-foreground","children":"Therapeutics — Block, Degrade & Clear Spike"}],["$","p",null,{"className":"mt-3 max-w-3xl text-lg leading-relaxed text-muted-foreground","children":"Catalog of COVID-19, Long COVID, and PASC interventions proposed to neutralize, enzymatically degrade, or physically remove spike protein — with explicit clinical support assessment (RCT, authorized, pilot, or preclinical only)."}]]}]
4:["$","aside",null,{"role":"note","aria-label":"Medical disclaimer","className":"rounded-lg border border-amber-300/60 bg-amber-50 px-4 py-3 text-sm text-amber-950 dark:border-amber-700/50 dark:bg-amber-950/40 dark:text-amber-100","children":["$","div",null,{"className":"flex gap-3","children":[["$","$La",null,{"iconNode":[["path",{"d":"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3","key":"wmoenq"}],["path",{"d":"M12 9v4","key":"juzpu7"}],["path",{"d":"M12 17h.01","key":"p32p05"}]],"className":"lucide-triangle-alert mt-0.5 h-4 w-4 shrink-0 text-amber-600 dark:text-amber-400","aria-hidden":"true"}],["$","p",null,{"children":[["$","strong",null,{"children":"Disclaimer:"}]," This is not medical advice. Consult a healthcare professional. Data is evolving and subject to scientific revision."]}]]}]}]
5:["$","div",null,{"className":"mt-8","children":["$","$Lb",null,{}]}]
6:["$","section",null,{"className":"mt-8 rounded-xl border border-border bg-card p-6","children":[["$","h2",null,{"className":"text-lg font-semibold text-foreground","children":"Clinical support legend"}],["$","ul",null,{"className":"mt-3 space-y-2 text-sm text-muted-foreground","children":[["$","li",null,{"children":[["$","strong",null,{"children":"FDA-approved/authorized"}]," — Regulatory approval for acute COVID-19 or prophylaxis; not necessarily long COVID or vaccine-spike clearance."]}],["$","li",null,{"children":[["$","strong",null,{"children":"RCT positive/negative"}]," — Randomized trial outcomes for claimed indication."]}],["$","li",null,{"children":[["$","strong",null,{"children":"Case series / pilot"}]," — Small human studies (e.g., Achleitner apheresis long-COVID cohort)."]}],["$","li",null,{"children":[["$","strong",null,{"children":"In vitro only"}]," — No robust human efficacy (e.g., nattokinase 2.5–25 µg/mL cell-free degradation)."]}],["$","li",null,{"children":[["$","strong",null,{"children":"Theoretical"}]," — Review or pharmacogenomic rationale without clinical validation."]}]]}]]}]
7:["$","section",null,{"className":"mt-6 rounded-xl border border-amber-200 bg-amber-50 p-6 dark:border-amber-900 dark:bg-amber-950/30","children":[["$","h2",null,{"className":"text-lg font-semibold text-amber-900 dark:text-amber-100","children":"Clinical caution"}],["$","p",null,{"className":"mt-2 text-sm text-amber-800 dark:text-amber-200","children":"No intervention is established standard of care for vaccine-derived spike clearance. Halma et al. caution against nattokinase and bromelain in pregnancy/breastfeeding due to bleeding risk."}],["$","div",null,{"className":"mt-4","children":["$","ul",null,{"className":"mt-2 space-y-1","children":[["$","li","halma2025",{"className":"text-sm text-muted-foreground","children":["$","a",null,{"href":"https://onlinelibrary.wiley.com/doi/full/10.1155/av/7990876","target":"_blank","rel":"noopener noreferrer","className":"text-[#e64a19] hover:text-[#ff9800] hover:underline","children":["Halma MTJ, et al."," ","The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury",". ",["$","em",null,{"children":"Advances in Virology"}]," (",2025,")",["."," ",["$","span",null,{"className":"font-mono text-xs","children":["doi:","10.1155/av/7990876"]}]]]}]}],["$","li","halmaAutophagy2024",{"className":"text-sm text-muted-foreground","children":["$","a",null,{"href":"https://doi.org/10.1016/j.endmts.2024.100163","target":"_blank","rel":"noopener noreferrer","className":"text-[#e64a19] hover:text-[#ff9800] hover:underline","children":["Halma MTJ, Marik PE, Saleeby YM"," ","Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology",". ",["$","em",null,{"children":"Endocrine and Metabolic Science"}]," (",2024,")",["."," ",["$","span",null,{"className":"font-mono text-xs","children":["doi:","10.1016/j.endmts.2024.100163"]}]]]}]}],["$","li","tanikawa2022",{"className":"text-sm text-muted-foreground","children":["$","a",null,{"href":"https://www.mdpi.com/1420-3049/27/23/8405","target":"_blank","rel":"noopener noreferrer","className":"text-[#e64a19] hover:text-[#ff9800] hover:underline","children":["Tanikawa T, et al."," ","Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2",". ",["$","em",null,{"children":"Molecules"}]," (",2022,")",["."," ",["$","span",null,{"className":"font-mono text-xs","children":["doi:","10.3390/molecules27238405"]}]]]}]}],["$","li","achleitner2023",{"className":"text-sm text-muted-foreground","children":["$","a",null,{"href":"https://pubmed.ncbi.nlm.nih.gov/37291234/","target":"_blank","rel":"noopener noreferrer","className":"text-[#e64a19] hover:text-[#ff9800] hover:underline","children":["Achleitner M, et al."," ","Clinical improvement of long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis",". ",["$","em",null,{"children":"Molecular Psychiatry"}]," (",2023,")",["."," ",["$","span",null,{"className":"font-mono text-xs","children":["doi:","10.1038/s41380-023-02084-1"]}]]]}]}],["$","li","spearTrial",{"className":"text-sm text-muted-foreground","children":["$","a",null,{"href":"https://clinicaltrials.gov/","target":"_blank","rel":"noopener noreferrer","className":"text-[#e64a19] hover:text-[#ff9800] hover:underline","children":["ClinicalTrials.gov"," ","SPEAR Trial — spike protein apheresis research",". ",["$","em",null,{"children":"Clinical trial registry"}]," (",2024,")","$undefined"]}]}],["$","li","recoverTrial",{"className":"text-sm text-muted-foreground","children":["$","a",null,{"href":"https://recovercovid.org/","target":"_blank","rel":"noopener noreferrer","className":"text-[#e64a19] hover:text-[#ff9800] hover:underline","children":["NIH RECOVER Initiative"," ","RECOVER — Researching COVID to Enhance Recovery",". ",["$","em",null,{"children":"NIH program"}]," (",2024,")","$undefined"]}]}]]}]}]]}]
8:["$","script","script-0",{"src":"/_next/static/chunks/40jyur0wxtonc.js","async":true}]
9:["$","$Lc",null,{"children":["$","$d",null,{"name":"Next.MetadataOutlet","children":"$@e"}]}]
e:null